TickerFacts.

Neumora Therapeutics, Inc. (NMRA): Shareholders' Equity

Annual figures by period end, from SEC filings.

$103.87M
As of 2025-12-31
$44.52M
As of 2026-06-30
$469.08M2022-12-31: -$446.85M2023-12-31: $469.08M2024-12-31: $287.06M2025-12-31: $103.87M$103.87M
2022-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$103.87M-63.8%2026-03-30, Balance as of period end
2024-12-31$287.06M-38.8%2026-03-30, Balance as of period end
2023-12-31$469.08Mn/m2025-03-03, Balance as of period end
2022-12-31-$446.85Mn/a2025-03-03, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Neumora Therapeutics, Inc. (NMRA)2025-12-31$103.87M-63.8%
Editas Medicine, Inc. (EDIT)2025-12-31$27.29M-79.7%
Vaxart, Inc. (VXRT)2025-12-31$87.80M+49.0%
Inhibikase Therapeutics, Inc. (IKT)2025-12-31$172.90M+82.3%
Instil Bio, Inc. (TIL)2025-12-31$113.87M-32.8%
Caribou Biosciences, Inc. (CRBU)2025-12-31$122.17M-51.7%
Protara Therapeutics, Inc. (TARA)2025-12-31$196.41M+17.5%
Sutro Biopharma, Inc. (STRO)2025-12-31-$132.45Mn/m
SAB Biotherapeutics, Inc. (SABS)2025-12-31$151.49M+483.4%

Compare NMRA, EDIT, VXRT, IKT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗